276 related articles for article (PubMed ID: 34213392)
1. Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice.
Dufu K; Williams AT; Muller CR; Walser CM; Lucas A; Eaker AM; Alt C; Cathers BE; Oksenberg D; Cabrales P
Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H400-H411. PubMed ID: 34213392
[TBL] [Abstract][Full Text] [Related]
2. GBT1118, a potent allosteric modifier of hemoglobin O
Dufu K; Yalcin O; Ao-Ieong ESY; Hutchaleelala A; Xu Q; Li Z; Vlahakis N; Oksenberg D; Lehrer-Graiwer J; Cabrales P
Am J Physiol Heart Circ Physiol; 2017 Aug; 313(2):H381-H391. PubMed ID: 28526710
[TBL] [Abstract][Full Text] [Related]
3. The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia.
Al Balushi H; Dufu K; Rees DC; Brewin JN; Hannemann A; Oksenberg D; Lu DC; Gibson JS
Physiol Rep; 2019 Mar; 7(6):e14027. PubMed ID: 30916477
[TBL] [Abstract][Full Text] [Related]
4. GBT1118, a compound that increases the oxygen affinity of hemoglobin, improves survival in murine hypoxic acute lung injury.
Putz ND; Shaver CM; Dufu K; Li CM; Xu Q; Hutchaleelaha A; Lehrer-Graiwer J; Majka SM; Ware LB; Bastarache JA
J Appl Physiol (1985); 2018 Apr; 124(4):899-905. PubMed ID: 29357510
[TBL] [Abstract][Full Text] [Related]
5. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
[TBL] [Abstract][Full Text] [Related]
6. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA
J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS
Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781
[TBL] [Abstract][Full Text] [Related]
8. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
9. Effects of GBT1118, a voxelotor analog, on intestinal pathophysiology in sickle cell disease.
Haroun E; Dutta D; Lim SH
Br J Haematol; 2023 Jul; 202(1):184-194. PubMed ID: 37052197
[TBL] [Abstract][Full Text] [Related]
10. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
11. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks.
Hebbel RP; Hedlund BE
Am J Hematol; 2018 Mar; 93(3):321-325. PubMed ID: 29150874
[No Abstract] [Full Text] [Related]
12. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
[TBL] [Abstract][Full Text] [Related]
13. Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis.
Geng X; Dufu K; Hutchaleelaha A; Xu Q; Li Z; Li CM; Patel MP; Vlahakis N; Lehrer-Graiwer J; Oksenberg D
Physiol Rep; 2016 Sep; 4(17):. PubMed ID: 27624688
[TBL] [Abstract][Full Text] [Related]
14. Localized increase of tissue oxygen tension by magnetic targeted drug delivery.
Liong C; Ortiz D; Ao-ieong E; Navati MS; Friedman JM; Cabrales P
Nanotechnology; 2014 Jul; 25(26):265102. PubMed ID: 24920392
[TBL] [Abstract][Full Text] [Related]
15. Increased hemoglobin O2 affinity protects during acute hypoxia.
Yalcin O; Cabrales P
Am J Physiol Heart Circ Physiol; 2012 Aug; 303(3):H271-81. PubMed ID: 22636677
[TBL] [Abstract][Full Text] [Related]
16. Quercetin Completely Ameliorates Hypoxia-Reoxygenation-Induced Pathophysiology Severity in NY1DD Transgenic Sickle Mice: Intrinsic Mild Steady State Pathophysiology of the Disease in NY1DD Is Also Reversed.
Thangaswamy S; Branch CA; Ambadipudi K; Acharya SA
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680105
[TBL] [Abstract][Full Text] [Related]
17. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
Abdulmalik O; Pagare PP; Huang B; Xu GG; Ghatge MS; Xu X; Chen Q; Anabaraonye N; Musayev FN; Omar AM; Venitz J; Zhang Y; Safo MK
Sci Rep; 2020 Nov; 10(1):20277. PubMed ID: 33219275
[TBL] [Abstract][Full Text] [Related]
18. Rheological Impact of GBT1118 Cessation in a Sickle Mouse Model.
Kanne CK; Nebor D; Pochron M; Oksenberg D; Sheehan VA
Front Physiol; 2021; 12():742784. PubMed ID: 34630162
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
[TBL] [Abstract][Full Text] [Related]
20. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model.
Dufu K; Alt C; Strutt S; Partridge J; Tang T; Siu V; Liao-Zou H; Rademacher P; Williams AT; Muller CR; Geng X; Pochron MP; Dang AN; Cabrales P; Li Z; Oksenberg D; Cathers BE
Br J Haematol; 2023 Jul; 202(1):173-183. PubMed ID: 36960712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
